Why Is Scienture Holdings Stock (SCNX) Up Today?

Scienture Holdings SCNX +49.47% ▲ stock was on the rise Wednesday after the health services IT company announced a commercial expansion for its Rezenopy Nasal Spray. The company has formalized multiple commercial Group Purchasing Organization (GPO) agreements for the product with more than 5,000 healthcare institutions.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

With this agreement, hospitals, clinics, and nursing homes across the U.S. will start using Rezenopy Nasal Spray. The company said that this represents a potential 60% penetration into the U.S. institutional market. It also opens the way for the company’s product to be used by first responders, EMS providers, and rehabilitation centers.

Shankar Hariharan, Executive Chairman and co-CEO of Scienture Holdings, said, “Institutional procurement channels are a key driver of growth for emergency overdose treatments. Through these GPO partnerships, we are significantly expanding our presence across hospitals, EMS providers, and rehabilitation centers, creating a scalable pathway for the adoption of REZENOPY™. We expect broader availability through these institutional channels to drive adoption and strengthen our growth trajectory as we scale our commercial operations.”

Scienture Holdings Stock Rallies Today

Scienture Holdings stock was up 45.64% in pre-market trading on Wednesday, following a slight dip yesterday. The stock has fallen 23.82% year-to-date and has decreased 69.17% over the past 12 months.

With today’s news came strong trading for SCNX stock, as more than 44 million shares changed hands. That’s well above the company’s three-month average daily trading volume of about 4.08 million shares.

Is Scienture Holdings Stock a Buy, Sell, or Hold?

Turning to Wall Street, only one analyst has covered Scienture Holdings over the past three months. Maxim Group’s Naz Rahman rated the stock a Buy with a $1.50 price target, representing a potential 286.1% upside for the shares.

Disclaimer & DisclosureReport an Issue